drugset

drugset / Trial / NCT03412383

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT03412383 ↗

Phase 2 Unknown 14 enrolled Peking Union Medical College

NaSingle-groupOpen-labelTreatment

Summary

A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Timeline

Start: 2018-02-20
Primary completion: 2019-01-25
Completion: 2019-06-25

Publications

Yi Z, Feng K, Lv D, Guan Y, Shao Y, Ma F, Xu B. Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer. Signal Transduct Target Ther. 2024 Dec 9;9(1):345. doi: 10.1038/s41392-024-02047-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pyrotinib	Small molecule	400 mg	—

Indications